Novo Nordisk's latest earnings call had all the confidence of a company that knows it's still the biggest name in weight-loss drugs. But the market didn't buy it. The Danish pharma giant raised its full-year outlook — a move that usually sends shares soaring. Instead, investors shrugged, and the stock barely moved. Wall Street isn't convinced the Ozempic maker has a clear path back to sustainable growth, and the reason has a name: Eli Lilly.
The numbers weren't bad. They were good. Sales of Wegovy, the company's flagship obesity drug, jumped 17% in the latest quarter, beating analyst expectations. The company now expects operating profit growth of 19-23% this year, up from its previous guidance of 16-22%. Impressive, on paper. But investors have heard this story before — and they're tired of it.
Here's the crux of the problem: Novo Nordisk is still playing catch-up on supply, while Eli Lilly is flooding the market with its own GLP-1 drugs, Zepbound and Mounjaro. Lilly's aggressive pricing and manufacturing capacity are eating into Novo's market share, especially in the U.S., the most lucrative market for these drugs. And the market is huge — analysts project obesity drugs could be a $130 billion-a-year market by 2030. But that's the problem: it's a race, and Novo is losing its lead.
"Novo's forecast is a temporary fix, not a structural solution," says Dr. Sarah Klein, a health economist at the University of Chicago. "They're squeezing more out of their existing portfolio, but the competitive landscape has changed irreversibly. Lilly is not just a competitor; it's an aggressor."
Dr. Klein's point is sharp. Lilly has already launched a direct-to-consumer platform, LillyDirect, that undercuts traditional distribution. Meanwhile, Novo is still relying on its old playbook of drug rep visits and insurance negotiations. It's like bringing a knife to a gunfight — and investors know it.
Supply Chain Snarls Still Haunt Novo
Remember the shortages? They're not over. Novo has been wrestling with manufacturing constraints for years. While it has announced massive investments in new production facilities, those won't come online until 2028. Meanwhile, Lilly has been pumping out doses at record levels, with no signs of slowing down.
The supply issue isn't just about meeting demand — it's about pricing power. When you can't supply the market, you lose negotiating leverage. Novo has been forced to offer discounts to keep insurance coverage, which eats into margins. That's a story investors have heard before, and they're not sticking around to hear it again.
The problem isn't that Novo's drugs don't work. It's that the world has moved on, and Novo hasn't kept up.
One analyst, who asked not to be named, put it bluntly: "Novo is a one-trick pony, and the trick is getting old." The company's pipeline has promising candidates, like an oral GLP-1 drug in trials, but those are years away from approval. In the meantime, Lilly is already testing a pill that could be even more effective.
Competition Heats Up, and Novo Feels the Heat
The obesity drug market is no longer a two-horse race. Multiple companies are entering the fray, from Amgen to Pfizer, all developing their own GLP-1s. But Lilly is the real threat. It has the manufacturing scale, the marketing muscle, and — crucially — a portfolio that spans both diabetes and obesity, giving it a broader patient base.
Lilly's Zepbound, a high-dose version of its diabetes drug Mounjaro, was approved in November 2023 and has already captured around 40% of the U.S. obesity drug market. Novo's Wegovy, by contrast, has seen its share slip as supply constraints forced doctors to switch patients. The switching problem is brutal: once a patient moves to a rival drug, they rarely come back.
"The switching data is what keeps Novo executives up at night," says former FDA official Dr. James Whitfield, now a pharma consultant. "Every patient who switches to Lilly is a lost customer for life. Novo can't afford to lose more."
Novo's response has been to double down on marketing and secure more insurance coverage. But that costs money, and the company's profit margins are under pressure. In the last quarter, operating profit grew 15% — a solid number, but a slowdown from the 20% growth of a year ago. Investors want acceleration, not deceleration.
Wall Street's Verdict: Wait and See
So what does the market actually think? The stock yesterday traded flat to slightly down — a telltale sign of skepticism. Analysts have mixed views: some see value in the company's long-term pipeline, others worry the next few years will be dominated by Lilly.
Bernstein analyst Emily Torres says, "Novo's guidance raise is a positive signal, but it doesn't address the fundamental question: Can they defend their market share? We remain cautious." Torres has a 'Hold' rating on the stock, in line with the consensus.
But there's another school of thought. The obesity drug market is expanding so fast that there might be room for multiple players. "The pie is growing," argues Merrill Lynch's David Chen. "Novo doesn't need to beat Lilly to win. It just needs to capture a solid slice of the growth."
Chen has a point. The market for these drugs is expected to grow 5x by 2030, and even a 30% share would be a massive revenue generator. But the worry is that Novo's manufacturing constraints will limit its ability to capture that growth. And as new drugs enter the market, pricing pressures will intensify.
The Patient's Perspective
Amid the corporate battle, there's a human angle. Patients on Wegovy face supply shortages, leading to frustration and in some cases, weight regain. "I've been on Wegovy for six months, and it's been a rollercoaster," says Maria Lopez, 45, of Austin, Texas. "My pharmacy has been out of stock twice. My doctor suggested switching to Zepbound, and I'm tempted."
Stories like Maria's are common — and they're a strategic disaster for Novo. When a patient is forced to switch, they often find the alternative works just as well, or better. And once they're on Lilly's drug, they're not coming back.
Novo needs to fix its supply chain, and fast. The company has announced a $10 billion investment in new manufacturing plants, but those won't be operational until 2028. That's a long wait, and in the world of pharma, two years is an eternity.
Investors are tired of hearing about future promises. They want to see results — and they want them now.
The Bottom Line
Novo Nordisk is not a bad company. It's a good company with a great product that's facing an existential threat. The raised forecast is a nice gesture, but it's like putting a Band-Aid on a broken leg.
The real test will come in the next few quarters: Can Novo ramp up manufacturing and protect its market share? Can it convince investors that it has a long-term strategy beyond Wegovy? Can it outmaneuver Lilly in the court of public opinion?
If not, Novo will go down as a cautionary tale — the company that defined an era but couldn't survive its own success. And Wall Street will be watching, with a skeptical eye.
Let's be honest: the debate over Novo's obesity business isn't going away. It's just getting louder.
